Treatment of inflammatory bowel disease (IBD)

Aberra, 2003, Corticosteroids and immunomodulators, postoperative infectious complication risk in inflammatory bowel disease, Gastroenterology, 125, 320, 10.1016/S0016-5085(03)00883-7

Arnold, 2002, Preliminary study of ciprofloxacin in active Crohn’s disease, Inflamm Bowel Dis, 8, 10, 10.1097/00054725-200201000-00002

Barnes, 1997, Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases, N Engl J Med, 336, 1066, 10.1056/NEJM199704103361506

Bello, 1991, Alternate-day prednisone treatment and treatment maintenance in Crohn’s disease, Am J Gastroenterol, 86, 460

Bibiloni, 2005, VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis, Am J Gastroenterol, 100, 1539, 10.1111/j.1572-0241.2005.41794.x

Camma, 1997, Mesalamine in the maintenance treatment of Crohn’s disease, A meta-analysis adjusted for confounding variables, Gastroenterology, 113, 1465, 10.1053/gast.1997.v113.pm9352848

Carrier, 2003, Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin 2- and ß2-microglobulin-deficient mice, Cancer Epidemiol Biomarkers Prev, 12, 1262

Connell, 1994, Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease, Lancet, 343, 1249, 10.1016/S0140-6736(94)92150-4

Cuzzocrea, 2001, Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis, Eur J Pharmacol, 432, 79, 10.1016/S0014-2999(01)01427-3

Dotan, 2005, Probiotics in inflammatory bowel disease, possible mechanisms of action, Curr Opin Gastroenterol, 21, 426

Farrell, 2003, Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease, A randomized, controlled trial, Gastroenterology, 124, 917, 10.1053/gast.2003.50145

Farrell, 2000, High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy, Gastroenterology, 118, 279, 10.1016/S0016-5085(00)70210-1

Faubion, 2001, The natural history of corticosteroid therapy for inflammatory bowel disease, a population-based study, Gastroenterology, 121, 255, 10.1053/gast.2001.26279

Feagan, 2000, A randomised controlled trial of methotrexate (MTX) as a maintenance therapy for chronically active Crohn’s disease (CD, New Eng J Med, 342, 1627, 10.1056/NEJM200006013422202

Fernandes-Banares, 1999, Randomised clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis, Am J Gastroenterol, 2, 427, 10.1111/j.1572-0241.1999.872_a.x

Fiocchi, 1998, Inflammatory bowel disease, etiology and pathogenesis, Gastroenterology, 115, 182, 10.1016/S0016-5085(98)70381-6

Francella, 2003, The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease, A retrospective cohort study, Gastroenterology, 124, 9, 10.1053/gast.2003.50014

Furrie, 2005, Synbiotic therapy (Bifidobacteium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis, a randomised controlled pilot trial, Gut, 54, 242, 10.1136/gut.2004.044834

Gionchetti, 2003, Prophylaxis of pouchitis onset with probiotic therapy, a double-blind, placebo-controlled trial, Gastroenterology, 124, 1202, 10.1016/S0016-5085(03)00171-9

Greenberg, 1994, Oral budesonide for active Crohn’s disease, New Eng J Med, 331, 836, 10.1056/NEJM199409293311303

Grisham, 1994, Oxidants and free radicals in inflammatory bowel disease, Lancet, 344, 859, 10.1016/S0140-6736(94)92831-2

Guslandi, 2003, A pilot trial of Saccharomyces boulardii in ulcerative colitis, Eur J Gastroenterol Hepatol, 15, 697, 10.1097/00042737-200306000-00017

Haber, 1986, Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease, Gastroenterology, 91, 982, 10.1016/0016-5085(86)90703-1

Hanauer, 1994, Medical therapy of inflammatory bowel disease, Med Clin North Am, 78, 1413, 10.1016/S0025-7125(16)30108-0

Hawthorne, 1992, Treatment of ulcerative colitis with fish oil supplementation, a prospective 12 month randomized controlled trial, Gut, 33, 922, 10.1136/gut.33.7.922

Herias, 2005, Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice, Int J Food Microbiol, 25, 143, 10.1016/j.ijfoodmicro.2004.11.032

Hofer, 2003, Oral budesonide in management of Crohn’s disease, Ann Pharmacother, 37, 1457, 10.1345/aph.1D059

Jowett, 2004, Influence of dietary factors on the clinical course of ulcerative colitis, a prospective cohort study, Gut, 53, 1479, 10.1136/gut.2003.024828

Karimi, 2005, Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn’s disease, a pilot study, Drugs Today (Barc, 41, 453, 10.1358/dot.2005.41.7.917341

Korelitz, 1993, Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease, Am J Gastroenterol, 88, 1198

Korelitz, 1998, Post-operative prophylaxis with 6-MP, 5-ASA, or placebo in Crohn’s disease, a 2-year multicenter trial, Gastroenterology, 114, A4141, 10.1016/S0016-5085(98)84115-2

Langmead, 2002, Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease, an in vitro study, Aliment Pharmacol Ther, 16, 197, 10.1046/j.1365-2036.2002.01157.x

Langmead, 2004, Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis, Aliment Pharmacol Ther, 19, 739, 10.1111/j.1365-2036.2004.01902.x

Langmead, 2004, Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro, Aliment Pharmacol Ther, 19, 521, 10.1111/j.1365-2036.2004.01874.x

Lichtinger, 1994, Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N Engl J Med, 330, 1841, 10.1056/NEJM199406303302601

Macfarlane, 2005, Mucosal bacteria in ulcerative colitis, Br J Nutr, 93, S67, 10.1079/BJN20041347

MacLean, 2005, Systematic review of the effects of omega-3 fatty acids in inflammatory bowel disease, Am J Clin Nutr, 82, 611, 10.1093/ajcn/82.3.611

Malolepszy, 1977, Sodium cromoglycate therapy in ulcerative colitis, Acta Allergol, 13, 82

Mazzon, 2005, Thalidomide treatment reduces colon injury induced by experimental colitis, Shock, 23, 556

Meister, 2005, Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture, differential effects on ulcerative colitis and Crohn’s disease, World J Gastroenterol, 21, 7466, 10.3748/wjg.v11.i47.7466

Meyers, 1995, Medical therapy of Crohn’s disease. In: Inflammatory Bowel Disease, 695

Middleton, 2002, A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis, Aliment Pharmacol Ther, 16, 1131, 10.1046/j.1365-2036.2002.01286.x

Panaccione, 2010, Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease, Aliment Pharmacol Ther, 31, 1296, 10.1111/j.1365-2036.2010.04304.x

Papadakis, 2000, The role of chemokines and chemokine receptors in mucosal inflammation, Inflamm Bowel Dis, 6, 303, 10.1097/00054725-200011000-00007

Pearson, 1995, Azathioprine and mercaptopurine in Crohn’s disease. A meta-analysis, Ann Intern Med, 123, 132, 10.7326/0003-4819-123-2-199507150-00009

Prantera, 1999, Mesalamine in the treatment of mild to moderate active Crohn’s ileitis, results of a randomised multicenter trial, Gastroenterology, 116, 521, 10.1016/S0016-5085(99)70172-1

Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn’s disease, New Eng J Med, 340, 1398, 10.1056/NEJM199905063401804

Rutgeerts, 2004, Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease, Gastroenterology, 126, 402, 10.1053/j.gastro.2003.11.014

Rutgeerts, 1995, Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection, Gastroenterology, 108, 1617, 10.1016/0016-5085(95)90121-3

Ryder, 1990, Rectal bismuth subsalicylate as therapy for ulcerative colitis, Aliment Pharmacol Ther, 4, 333, 10.1111/j.1365-2036.1990.tb00480.x

Sakamoto, 2005, Dietary risk factors for inflammatory bowel disease, a multicenter case-control study in Japan, Inflamm Bowel Dis, 11, 154, 10.1097/00054725-200502000-00009

Sandborn, 1995, A critical review of cyclosporine therapy in inflammatory bowel disease, Inflamm Bowel Dis, 1, 48, 10.1097/00054725-199503000-00006

Sandborn, 2007, Certolizumab pegol for the treatment of Crohn’s disease, N Engl J Med, 357, 228, 10.1056/NEJMoa067594

Sands, 2004, Infliximab maintenance therapy for fistulizing Crohn’s disease, New Engl J Med, 350, 876, 10.1056/NEJMoa030815

Sartor, 1995, Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease, Gastroenterol Clin North Am, 24, 475, 10.1016/S0889-8553(21)00207-7

Sartor, 1999, Microbial factors in the pathogenesis of Crohn’s disease, ulcerative colitis and experimental intestinal inflammation. In: Inflammatory Bowel Disease. 5th edn., Eds, Kirsner JB, Hanauer S, Saunders, Philadelphia, 153

Shah, 2007, Treatment of diarrhea in patients with inflammatory bowel disease, concepts and cautions, Rev Gastroenterol Disord, 7, S3

Steinhart, 2003, Corticosteroids for maintenance of remission in Crohn’s disease, Cochrane Database Syst Rev, CD000301

Sutherland, 1991, Double blind, placebo-controlled trial of metronidazole in Crohn’s disease, Gut, 32, 1071, 10.1136/gut.32.9.1071

Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease, New Eng J Med, 337, 1029, 10.1056/NEJM199710093371502

Taylor, 1999, Inhibition of cytokine-induced nitric oxide synthase expression by gene transfer of adenoviral IκBα, Surgery, 126, 142, 10.1016/S0039-6060(99)70147-9

Vakil, 1989, Steroid-related osteonecrosis in inflammatory bowel disease, Gastroenterology, 96, 62, 10.1016/0016-5085(89)90764-6

Vasiliauskas, 1999, An open-label, step-wise dose-escalating pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease, Gastroenterology, 117, 1278, 10.1016/S0016-5085(99)70277-5

Wahl, 1998, Sulfasalazine, a potent and specific inhibitor of nuclear factor kappa B, J Clin Invest, 101, 1163, 10.1172/JCI992